http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0491789-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01c1e0bc0628f76dea731cda5a666ca1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-52 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 |
| filingDate | 1990-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b93fc5b4b6f645eb1088696cc6deb31a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c70d9e3355a5d6430cb4b040f964aa1a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8ffa6c0a1efdd41ec0b59f5a18d3ad1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0aca883a31f9f5758d0eb4dd5450b132 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db6cd4106eca31f3ee6b5d38d8e1e815 |
| publicationDate | 1992-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H0491789-A |
| titleOfInvention | New plasminogen activation factor derivative and production thereof |
| abstract | PURPOSE: To obtain a tissue-type plasminogen activation factor derivative having long half-life in blood and high fibrin-dissolution activity and containing a specific amino acid sequence by culturing a transformant having a specific DNA sequence. n CONSTITUTION: A manifestation vector having a DNA sequence coding a specific tissue-type plasminogen activation factor (abbreviated as TPA) derivative is constructed. The TPA derivative has a structure of TPA provided that the amino acids from the 37th to the 41st counted from the N-terminal are substituted with hydrophobic amino acids such as valine and amino acids at specific positions such as 161st, 162nd and 165th (or 115th) are also substituted. The manifestation vector is introduced into a cultured animal cell such as CHO-K1 strain used as a host cell and the cell is cultured. The cultured product is recovered and purified to obtain the objective TPA derivative. Since the TPA derivative has improved durability in blood and keeps the thrombolytic activity comparable to natural TPA, it can be effectively used for the remedy of thrombosis. n COPYRIGHT: (C)1992,JPO&Japio |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8256766-B2 |
| priorityDate | 1990-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6287 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558427 |
Total number of triples: 25.